Clinical Trials Logo

Stage IV Skin Melanoma clinical trials

View clinical trials related to Stage IV Skin Melanoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03719131 Active, not recruiting - Clinical trials for Unresectable Melanoma

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Start date: June 5, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies whether rituximab and hyaluronidase human (Rituxan Hycela) can prevent immune related adverse events in participants with stage III-IV melanoma that cannot be removed by surgery who are undergoing nivolumab and ipilimumab therapy.

NCT ID: NCT03154190 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Start date: August 8, 2017
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer. Health care coach support may help cancer patients to make decisions about their care that matches what is important to them with symptom management.

NCT ID: NCT02876068 Active, not recruiting - Solid Neoplasm Clinical Trials

Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies

Start date: May 2011
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of cediranib maleate and selumetinib in treating patients with solid malignancies. Cediranib maleate and selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also stop the growth of tumor cells by blocking blood flow to the tumor.

NCT ID: NCT02654821 Active, not recruiting - Clinical trials for Stage IV Skin Melanoma

Study With T-cel Receptor Gene Therapy in Metastatic Melanoma

TCR
Start date: March 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Patients with stage IV melanoma (also eye melanoma) will be treated with TCR transduced cells.

NCT ID: NCT01307618 Active, not recruiting - Recurrent Melanoma Clinical Trials

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

Start date: February 2011
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is studying how well giving vaccine therapy together with or without recombinant interleukin-12 followed by daclizumab works in treating patients with melanoma that has spread to other places in the body. Vaccines made from peptides or antigens may help the body build an effective immune response to kill tumor cells. Recombinant interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating white blood cells to kill melanoma cells. Monoclonal antibodies, such as daclizumab, may decrease the number of regulatory T cells (T cells that suppress the activation of the immmune system) and may lead to a better immune response against melanoma. It is not yet known whether vaccine therapy is more effective with interleukin-12 and daclizumab in treating melanoma.